drugset / Trial / NCT01639599

Optimal Haloperidol Dose for Postoperative Nausea and Vomiting Prevention in High-risk Patients

NCT01639599

Completed 150 enrolled The Catholic University of Korea
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Low-dose haloperidol is known to be effective for the treatment of postoperative nausea and vomiting (PONV). However, precise dose-response studies have not been completed, especially in patients at high risk for PONV who require combination therapy. This study sought to identify the optimal dose of haloperidol that could be combined with dexamethasone without adverse effects in high-risk PONV patients receiving intravenous patient-controlled anesthesia (IV PCA) after gynecological laparoscopic surgery.

Timeline

Start
2012-03
Primary completion
2012-12
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Haloperidol Other / unclassified 1 mg Intravenous
Comparator Haloperidol Other / unclassified 2 mg Intravenous
Comparator Dexamethasone Small molecule 5 mg Intravenous